Literature DB >> 9230773

Temporal trends and factors associated with survival after Pneumocystis carinii pneumonia in California, 1983-1992.

J M Colford1, M Segal, F Tabnak, M Chen, R Sun, I Tager.   

Abstract

The authors investigated quarterly trends in survival after the diagnosis of Pneumocystis carinii pneumonia for 19,607 patients in California in the decade from January 1, 1983, through December 31, 1992. Subjects included all cases for whom P. carinii pneumonia was the initial (and only) acquired immunodeficiency syndrome (AIDS)-defining diagnosis as reported to the California human immunodeficiency virus/AIDS surveillance registry. There was a period of rapidly improving survival from approximately June 1986 until April 1988, coincident with the widespread introduction of antiretroviral therapy (zidovudine) and the institution of P. carinii pneumonia prophylaxis (with cotrimoxazole and pentamidine). There was no evidence, however, of meaningful improvements in survival for these patients after that period. The association of several covariates (risk transmission group, gender, race/ethnicity, certainty of P. carinii pneumonia diagnosis, age, region of residence, availability of CD4 count, and level of CD4 count) were also studied both by proportional hazards regression and by recursive partitioning (i.e., tree-based) survival analysis. The availability of a CD4 count (regardless of its level) was the single factor most strongly associated with survival (median survival 36 months among those with and 14 months among those without reported CD4 counts, p < 0.05). Data from this large, population-based surveillance registry of AIDS in California suggest that, despite earlier improvements in survival after the diagnosis of P. carinii pneumonia, the long-term survival of these patients remains poor (39% alive 2 years after diagnosis) and that no improvement in survival has occurred since 1988.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230773     DOI: 10.1093/oxfordjournals.aje.a009242

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Nonparametric survival estimation when death is reported with delay.

Authors:  A E Hubbard; M J Van der Laan; W Enanoria; J M Colford
Journal:  Lifetime Data Anal       Date:  2000-09       Impact factor: 1.588

2.  Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

Authors:  C Binquet; F Saillour; N Bernard; M B Rougier; F Leger; F Bonnal; F Dabis
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

3.  Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection.

Authors:  Taylor Eddens; Waleed Elsegeiny; Michael P Nelson; William Horne; Brian T Campfield; Chad Steele; Jay K Kolls
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

4.  Murine models of Pneumocystis infection recapitulate human primary immune disorders.

Authors:  Waleed Elsegeiny; Mingquan Zheng; Taylor Eddens; Richard L Gallo; Guixiang Dai; Giraldina Trevejo-Nunez; Patricia Castillo; Kara Kracinovsky; Hillary Cleveland; William Horne; Jonathan Franks; Derek Pociask; Mark Pilarski; John F Alcorn; Kong Chen; Jay K Kolls
Journal:  JCI Insight       Date:  2018-06-21

5.  Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.

Authors:  R F Miller; E Allen; A Copas; M Singer; S G Edwards
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

6.  Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.

Authors:  Peter D Walzer; Hannah E R Evans; Andrew J Copas; Simon G Edwards; Alison D Grant; Robert F Miller
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

7.  Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia.

Authors:  Fan Jin; Jing Xie; Huan-Ling Wang
Journal:  BMC Infect Dis       Date:  2021-05-14       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.